It became the dominant research IGF-1 reagent for cell-culture and animal work and has been cited in thousands of papers
CJC-1295 + ipamorelin are usually cycled 12 weeks on and 4 weeks off to reduce receptor desensitization
You enter a 2-month rest period
If you're not a fan of taking pills or capsules, this product is for you
Common uses in women: Hypothalamic amenorrhea: kisspeptin administration has been shown to increase LH in women with hypothalamic amenorrhea, offering a potential hormone-sparing route to restoring ovulation IVF oocyte maturation trigger: clinical trials (including a Phase 2 RCT published in PMC, 2018) demonstrated that subcutaneous kisspeptin-54 at 9.6 nmol/kg can trigger egg maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS), producing successful pregnancies without OHSS complications Hypoactive sexual desire disorder (HSDD): a randomized clinical trial of 32 premenopausal women (JAMA Network Open, 2022) found kisspeptin administration modulated brain processing of sexual and attraction stimuli in functional neuroimaging and correlated with reduced sexual aversion and distress Perimenopausal hormonal stabilization: early research suggests kisspeptin may support GnRH/LH pulsatility during the transitional perimenopause window when HPG axis instability is most pronounced Typical dosing range: In IVF clinical trials, kisspeptin-54 was administered as a single subcutaneous injection at 9.6 nmol/kg approximately 36 hours before oocyte retrieval, sometimes followed by a second dose 10 hours later
If you have any complaints or copyright issues related to this article, kindly contact the author above.
